Dr. Turners Interest
My research aims to understand the biology underlying the low success rates of smoking quitters. To do this, I investigate the genomic alterations resulting from chronic nicotine administration and withdrawal using ChIP-Seq and RNA-Seq technologies and how these changes impact both behavior as well as the concordant transcriptionally-driven circuitry adaptations. These altered preclinical genomic targets observed following chronic treatment and withdrawal are then candidates for SNP analysis in the smoking population.
In addition to understanding the key genomic mechanisms of nicotine dependence and withdrawal phenotypes, I am interested in how we might apply this knowledge to further personalized medicine.
Post Doctoral Fellowship, Neurogenetics
University of Pennsylvania (2012)
Doctor of Philosophy, Neuroscience
Georgetown University (2007)
Bachelor of Science, Biology
West Virginia University (2002)
- Mague SD, Port RG, McMullen ME, Carlson GC, Turner JR. Mouse model of OPRM1 (A118G) polymorphism has altered hippocampal function. Neuropharmacology. ., 2015. View in: PubMed
- Yohn NL, Turner JR, Blendy JA. Activation of a4ß2*/a6ß2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors. J Pharmacol Exp Ther. .349(2):348-54, 2014. PMCID: PMC3989801View in: PubMed
- Turner JR, Ray R, Lee B, Everett L, Xiang J, Jepson C, Kaestner KH, Lerman C, Blendy JA. Evidence from mouse and man for a role of neuregulin 3 in nicotine dependence. Mol Psychiatry. .19(7):801-10, 2013. PMCID: PMC3877725View in: PubMed
- Ortinski PI, Turner JR, Pierce RC. Extrasynaptic targeting of NMDA receptors following D1 dopamine receptor activation and cocaine self-administration. J Neurosci. .33(22):9451-61, 2013. PMCID: PMC3715961View in: PubMed
- Turner JR, Wilkinson DS, Poole RL, Gould TJ, Carlson GC, Blendy JA. Divergent functional effects of sazetidine-a and varenicline during nicotine withdrawal. Neuropsychopharmacology. .38(10):2035-47, 2013. PMCID: PMC3746688